Benjamin Edwards Inc. Raises Position in AbbVie Inc. $ABBV

Benjamin Edwards Inc. lifted its stake in shares of AbbVie Inc. (NYSE:ABBV) by 3.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 386,472 shares of the company’s stock after buying an additional 12,094 shares during the period. AbbVie comprises about 1.0% of Benjamin Edwards Inc.’s holdings, making the stock its 12th largest position. Benjamin Edwards Inc.’s holdings in AbbVie were worth $89,498,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also bought and sold shares of the company. Conning Inc. boosted its position in AbbVie by 7.1% during the 2nd quarter. Conning Inc. now owns 191,023 shares of the company’s stock valued at $35,458,000 after acquiring an additional 12,690 shares in the last quarter. Diversified Trust Co lifted its stake in shares of AbbVie by 23.6% in the 3rd quarter. Diversified Trust Co now owns 57,076 shares of the company’s stock valued at $13,215,000 after purchasing an additional 10,891 shares during the period. Dohj LLC boosted its position in shares of AbbVie by 41.8% during the second quarter. Dohj LLC now owns 4,529 shares of the company’s stock valued at $802,000 after purchasing an additional 1,335 shares in the last quarter. Permanent Capital Management LP purchased a new stake in AbbVie in the third quarter worth $720,000. Finally, Railway Pension Investments Ltd grew its stake in AbbVie by 33.0% in the third quarter. Railway Pension Investments Ltd now owns 853,949 shares of the company’s stock worth $197,723,000 after purchasing an additional 211,800 shares during the period. Institutional investors own 70.23% of the company’s stock.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Reports say AbbVie is in advanced talks to buy Revolution Medicines (market value ~ $16B), fueling speculation the deal would expand AbbVie’s oncology pipeline and justify a premium valuation. AbbVie in talks to buy biotech Revolution Medicines, WSJ reports
• Positive Sentiment: Market reaction reinforced the takeover narrative: Revolution Medicines and AbbVie shares rallied on takeover reports, as investors priced in strategic oncology upside and potential deal synergies. AbbVie, Revolution Medicines Stocks Gain on Report of Possible Acquisition
• Positive Sentiment: AbbVie expanded its ovarian‑cancer pipeline with a Phase 1, first‑in‑human ABBV‑901 trial update — a near‑term clinical development item that supports growth narrative beyond immunology specialties. AbbVie Expands Ovarian Cancer Pipeline With New First‑in‑Human ABBV‑901 Trial
• Neutral Sentiment: Ironwood’s surprise guidance and its LINZESS list‑price cut (AbbVie is the commercial partner) reshaped revenue/rebate dynamics for that franchise — a development that may indirectly affect AbbVie’s commercial results but whose net impact on ABBV is ambiguous. Ironwood Pharmaceuticals’ 2026 Guidance Shock Sparks a Major Re-Rating (ABBV)
• Neutral Sentiment: AbbVie scheduled its full‑year and Q4 2025 earnings release and conference call for Feb. 4 — a date investors will watch for guidance and clarity on growth drivers and any commentary on M&A. AbbVie to Host Full-Year and Fourth-Quarter 2025 Earnings Conference Call
• Neutral Sentiment: A UBS analyst reiterated a Hold rating, noting AbbVie’s premium valuation and long‑duration growth but a balanced risk/reward — a reminder some analysts view upside as tied to execution and potential M&A. AbbVie: Premium Valuation, Strong Long-Duration Growth, but Balanced Risk/Reward Supports Hold Rating
• Negative Sentiment: AbbVie denied media reports that it was in talks to buy Revolution Medicines, which could remove the acquisition catalyst and lead to some profit‑taking after the initial rally. AbbVie denies media reports of talks to buy Revolution Medicines

Wall Street Analyst Weigh In

A number of brokerages have recently commented on ABBV. Raymond James Financial set a $256.00 target price on shares of AbbVie in a report on Monday, November 3rd. UBS Group assumed coverage on shares of AbbVie in a research report on Wednesday. They set a “neutral” rating and a $240.00 price target for the company. Citigroup cut their price objective on shares of AbbVie from $240.00 to $235.00 and set a “neutral” rating on the stock in a report on Monday, November 3rd. Erste Group Bank downgraded shares of AbbVie from a “buy” rating to a “hold” rating in a research note on Tuesday, October 14th. Finally, Bank of America boosted their price target on AbbVie from $220.00 to $251.00 and gave the stock a “neutral” rating in a research report on Friday, October 3rd. Three research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $246.89.

AbbVie Price Performance

ABBV stock opened at $233.65 on Thursday. AbbVie Inc. has a 1-year low of $164.39 and a 1-year high of $244.81. The stock has a market capitalization of $412.95 billion, a P/E ratio of 177.01, a P/E/G ratio of 0.94 and a beta of 0.36. The business has a fifty day moving average price of $226.63 and a 200-day moving average price of $214.80.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The business had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. During the same quarter in the prior year, the business earned $3.00 EPS. The business’s revenue for the quarter was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be paid a $1.73 dividend. This is an increase from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.0%. AbbVie’s dividend payout ratio (DPR) is 496.97%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.